Drug Trial Radar · NCT04834024
MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
168
Planned (sponsor's estimate)
Start
Jun 2, 2021
Primary completion
Mar 2025
Study completion Mar 2025
Sponsor
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.
Conditions
- Follicular Lymphoma and Marginal Zone Lymphoma
Interventions
Recombinant Humanized Monoclonal Antibody MIL62, lenalinomideDrug
The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
lenalinomideDrug
The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (per IRC)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.